Edwards Lifesciences (EW) EBIT (2009 - 2026)

Edwards Lifesciences' EBIT history runs 18 years deep, the most recent figure standing at $477.6 million for Q1 2026.

• On a quarterly basis, EBIT rose 20.97% year-over-year to $477.6 million in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 5.44% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 8.3% from the prior year.
• EBIT advanced to $477.6 million in Q1 2026 per EW's latest filing, from $151.1 million in the prior quarter.
• Across five years, EBIT topped out at $477.6 million in Q1 2026 and bottomed at $151.1 million in Q4 2025.
• The 5-year median for EBIT is $365.9 million (2023), against an average of $352.0 million.
• Across the five-year window, EBIT jumped 75.42% in 2023 and sank 51.66% in 2025, its largest moves.
• Year by year, EBIT stood at $197.7 million in 2022, then soared by 75.42% to $346.8 million in 2023, then declined by 9.86% to $312.6 million in 2024, then sank by 51.66% to $151.1 million in 2025, then jumped by 216.08% to $477.6 million in 2026.
• Per Business Quant, the three latest EW EBIT figures stand at $477.6 million (Q1 2026), $151.1 million (Q4 2025), and $307.1 million (Q3 2025).